Vol 7, No 4 (2006): Practical Diabetology
Review article
Submitted: 2012-01-02
Published online: 2006-07-12
The role of the renin-angiotensin-aldosterone system blockade in preventing type 2 diabetes
Mariusz Dąbrowski, Elżbieta Kozek
DOI: 10.5603/cd.8553
·
Diabetologia Praktyczna 2006;7(4):265-279.
Vol 7, No 4 (2006): Practical Diabetology
Review articles (submitted)
Submitted: 2012-01-02
Published online: 2006-07-12
Abstract
The prevalence of type 2 diabetes is still increasing.
It causes both growing burden for health insurance
institutions and growing social costs of disability and
premature mortality related to diabetes. Searching
for methods which can reduce incidence of diabetes
and thus limit consequences of forthcoming epidemic
becomes urgent. It is well known that lifestyle
changes and some oral antidiabetic agents (metformin,
acarbose, troglitazone, pioglitazone) can reduce
risk of developing diabetes in persons with impaired
glucose tolerance. Such effect has been proven
also for statins (pravastatin), antiobesity agents
(orlistat) and for antihypertensive drugs.
In this paper, on the basis of several large scale randomized
clinical trials, the role of angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers
in prevention of type 2 diabetes is discussed. On the
basis of experimental studies postulated mechanisms
which can lead to reduction of the risk of developing
diabetes are also presented.
If thus observations will be confirmed by ongoing
clinical studies directed to prevention of type 2 diabetes, the medical world will obtain a weapon which
can diminish consequences and extent of expected
epidemic of type 2 diabetes.
Abstract
The prevalence of type 2 diabetes is still increasing.
It causes both growing burden for health insurance
institutions and growing social costs of disability and
premature mortality related to diabetes. Searching
for methods which can reduce incidence of diabetes
and thus limit consequences of forthcoming epidemic
becomes urgent. It is well known that lifestyle
changes and some oral antidiabetic agents (metformin,
acarbose, troglitazone, pioglitazone) can reduce
risk of developing diabetes in persons with impaired
glucose tolerance. Such effect has been proven
also for statins (pravastatin), antiobesity agents
(orlistat) and for antihypertensive drugs.
In this paper, on the basis of several large scale randomized
clinical trials, the role of angiotensin-converting
enzyme inhibitors and angiotensin receptor blockers
in prevention of type 2 diabetes is discussed. On the
basis of experimental studies postulated mechanisms
which can lead to reduction of the risk of developing
diabetes are also presented.
If thus observations will be confirmed by ongoing
clinical studies directed to prevention of type 2 diabetes, the medical world will obtain a weapon which
can diminish consequences and extent of expected
epidemic of type 2 diabetes.
Keywords
type 2 diabetes mellitus; prevention; angiotensin-converting enzyme inhibitor; angiotensin receptor blocker; hypertension; insulin resistance
Title
The role of the renin-angiotensin-aldosterone system blockade in preventing type 2 diabetes
Journal
Clinical Diabetology
Issue
Vol 7, No 4 (2006): Practical Diabetology
Article type
Review article
Pages
265-279
Published online
2006-07-12
Page views
603
DOI
10.5603/cd.8553
Bibliographic record
Diabetologia Praktyczna 2006;7(4):265-279.
Keywords
type 2 diabetes mellitus
prevention
angiotensin-converting enzyme inhibitor
angiotensin receptor blocker
hypertension
insulin resistance
Authors
Mariusz Dąbrowski
Elżbieta Kozek
About this article